Hummingbird Bioscience
Hummingbird Bioscience
Hummingbird Bioscience
  • About Us
  • Science
    • ADC Platform
    • Antibody Platform
    • Publications
  • Pipeline
    • HMBD-001
    • HMBD-501
  • News
  • Partnering
  • Patients
  • Contact
  • Join Us

    RelatedNews-HMBD-002

  • All
  • News
  • Publications & Posters
    • News
    • News - 2025

    Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics

    Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s HMBD-002 for further clinical development. Hummingbird…

    Continue Reading
    • News
    • News – 2024

    View Replay: 3rd Annual Virtual VISTA Symposium

    Hummingbird Bioscience and Dartmouth’s Geisel School of Medicine today announced that the 3rd Annual VISTA…

    Continue Reading
    • HMBD-002
    • Posters
    • Posters - 2024
    • Publications & Posters

    AACR 2024: The VISTA blocking antibody HMBD-002 promotes type-I interferon signaling and drives anti-tumor responses through macrophage reprograming and cytotoxic CD8+ T cell activation

    Continue Reading
    • News
    • News – 2024

    Hummingbird Bioscience and Dartmouth’s Geisel School of Medicine to Co-Host 3rd Annual Virtual VISTA Symposium on March 27, 2024

    Hummingbird Bioscience and Dartmouth’s Geisel School of Medicine today announced that the 3rd Annual VISTA…

    Continue Reading
    • News
    • News – 2024

    Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024

    Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat…

    Continue Reading
    • HMBD-002
    • Posters
    • Posters - 2023
    • Publications & Posters

    ASCO 2023: A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors

    Continue Reading
    • News
    • News - 2023

    Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023

    Continue Reading
    • HMBD-002
    • Posters
    • Posters - 2022
    • Publications & Posters

    SITC 2022: Anti-VISTA antibody HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T cell response

    Continue Reading
    • HMBD-002
    • Posters
    • Posters - 2022
    • Publications & Posters

    SITC 2022: Trial in Progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

    Continue Reading
    • News
    • News - 2022

    Hummingbird Bioscience Announces Two HMBD-002 Poster Presentations at the Society for Immunotherapy of Cancer 2022 Annual Meeting

    Continue Reading
  • 1
  • 2
  • →

Hummingbird Bioscience

The Galen
61 Science Park Road, #06-15
Singapore 117525


Hummingbird Bioscience Twitter Hummingbird Bioscience Twitter Hummingbird Bioscience LinkedinHummingbird Bioscience Linkedin Hummingbird Bioscience YouTube Hummingbird Bioscience YouTube
Subscribe to our updates
Registered Company No: 201505192N
PRIVACY POLICY | © 2025 Hummingbird Bioscience
  • About Us
  • Science
    • ADC Platform
    • Antibody Platform
    • Publications
  • Pipeline
    • HMBD-001
    • HMBD-501
  • News
  • Partnering
  • Patients
  • Contact
  • Join Us

What are you looking for?

Subscribe to our updates

    *indicates required

    You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website. For questions about this mailing list, please email communications@hummingbirdbio.com

    We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

    Close